Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

Xavier Poiré, MD, Ernesto Diaz-Flores, PhD, Rachel Joy Bergerson, Dorie Sher, B.S., Olatoyosi Odenike, MD, Kevin Shannon, MD, David Largaespada, PhD, Wendy Stock, MD

Blood (2009) 114 (22): 1032.

https://doi.org/10.1182/blood.V114.22.1032.1032

Published: 2009

Journal Articles

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Wendy Stock, MD, Ben Sanford, M.A., Gerard Lozanski, M.D., Ravi Vij, MD, John C. Byrd, Bayard L. Powell, MD, Meir Wetzler, MD, Dorie Sher, B.S., Colin Edwards, Ph.D., Michael Kelly, B.S., Sue Richards, Ph.D, Crystal Sung, PhD, Greg Malnassy, B.S., Eva Hoke, BA, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 838.

https://doi.org/10.1182/blood.V114.22.838.838

Published: 2009

Journal Articles

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Ivan M. Borrello, Hyam I. Levitsky, Wendy Stock, Dorie Sher, Lu Qin, Daniel J. DeAngelo, Edwin P. Alyea, Richard M. Stone, Lloyd E. Damon, Charles A. Linker, Daniel J. Maslyar, Kristen M. Hege

Blood (2009) 114 (9): 1736–1745.

https://doi.org/10.1182/blood-2009-02-205278

Published: 2009

Includes: Supplemental data

Journal Articles

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Olatoyosi M Odenike, John E. Godwin, Koen Van Besien, Dezheng Huo, Dorie Sher, Patrick Burke, Scott E. Smith, Margaret Green, Julia Melnick, James L Wade, Eric P. Lester, Rebecca B. Klisovic, Maria R. Baer, Richard A Larson, Wendy Stock

Blood (2008) 112 (11): 2809.

https://doi.org/10.1182/blood.V112.11.2809.2809

Published: 2008

Journal Articles

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML.

Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Stephen J. Brandt, Jingping Xie, Yanming Zhang, David H. Vesole, Richard A. Larson, Wendy Stock

Blood (2006) 108 (11): 1956.

https://doi.org/10.1182/blood.V108.11.1956.1956

Published: 2006

Journal Articles

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

Wendy Stock, MD, Richard Harvey, MD, Barry Moser, PhD, Dorie Sher, BS, Esther Schachter-Tokarz, BS, Matthew Myers, BS, James Slack, MD, Bayard Powell, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, James Feusner, MD, Cheryl Willman, MD, Robert Gallagher, MD

Blood (2006) 108 (11): 494.

https://doi.org/10.1182/blood.V108.11.494.494

Published: 2006

Journal Articles

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Olatoyosi M. Odenike, John E. Godwin, Koen van Besien, Dezheng Huo, Patrick J. Stiff, Dorie Sher, Nicole Klekowski, Margaret Green, Richard A. Larson, Wendy Stock

Blood (2006) 108 (11): 4923.

https://doi.org/10.1182/blood.V108.11.4923.4923

Published: 2006

Journal Articles

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Robert E. Gallagher, MD, Esther L. Schachter-Tokarz, B.A., Barry K. Moser, Ph.D., Dorie Sher, B.A., Elisabeth Paietta, Ph.D., Martin S. Tallman, M.D., Clara D. Bloomfield, M.D., Bayard L. Powell, M.D., Richard A. Larson, M.D., Frederick R. Appelbaum, M.D., Cheryl L. Willman, M.D., Richard C. Harvey, Ph.D., Wendy Stock, M.D.

Blood (2006) 108 (11): 2342.

https://doi.org/10.1182/blood.V108.11.2342.2342

Published: 2006

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

Journal Articles

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

Wendy Stock, MD, Jeffrey Johnson, MS, Daohai Yu, PhD, Diane Bennett, BSN, Dorie Sher, BS, Richard M. Stone, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Meir Wetzler, MD, James W. Vardiman, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 1833.

https://doi.org/10.1182/blood.V106.11.1833.1833

Published: 2005

Journal Articles

The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).

Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Matthew Myers, Stephen J. Brandt, Yanming Zhang, David H. Vesole, Richard A. Larson, Wendy Stock

Blood (2004) 104 (11): 264.

https://doi.org/10.1182/blood.V104.11.264.264

Published: 2004

Journal Articles

Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML).

Daniel J. DeAngelo, Edwin P. Alyea, Ivan M. Borrello, Hyam I. Levitsky, Wendy Stock, Dorie Sher, Lloyd E. Damon, Charles A. Linker, Amy Donnelly, Kristen M. Hege

Blood (2004) 104 (11): 441.

https://doi.org/10.1182/blood.V104.11.441.441

Published: 2004

Journal Articles

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Dorie Sher, BS, Jeffrey Johnson, PhD, Mariah Siddiqui, Michael A. Caligiuri, MD, Lloyd E. Damon, MD, George P. Canellos, MD, Charles Linker, MD, Bruce D. Cheson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 1652.

https://doi.org/10.1182/blood.V104.11.1652.1652

Published: 2004

Journal Articles

The IRS-Pathway Operates Distinctively From the Stat-Pathway in Hematopoietic Cells and Transduces Common and Distinct Signals During Engagement of the Insulin or Interferon-α Receptors

Shahab Uddin, Eleanor N. Fish, Dorie Sher, Concetta Gardziola, Oscar R. Colamonici, Merrill Kellum, Paula M. Pitha, Morris F. White, Leonidas C. Platanias

Blood (1997) 90 (7): 2574–2582.

https://doi.org/10.1182/blood.V90.7.2574

Published: 1997

NARROW

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

The Histone Deacetylase Inhibitor (HDI) Depsipeptide Has Differential Activity in Core Binding Factor AML.

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).

Posttransplant Immunotherapy with a GM-CSF-Based Tumor Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) for Acute Myeloid Leukemia (AML).

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

The IRS-Pathway Operates Distinctively From the Stat-Pathway in Hematopoietic Cells and Transduces Common and Distinct Signals During Engagement of the Insulin or Interferon-α Receptors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only